FY2025 EPS Estimates for Biogen Reduced by Cantor Fitzgerald

Biogen Inc. (NASDAQ:BIIB) – Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for shares of Biogen in a research report issued on Wednesday, April 9th. Cantor Fitzgerald analyst E. Schmidt now expects that the biotechnology company will earn $14.74 per share for the year, down from their previous estimate of $16.13. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share.

Several other equities analysts have also weighed in on BIIB. Piper Sandler restated a “neutral” rating and issued a $135.00 price objective (down from $138.00) on shares of Biogen in a report on Tuesday, February 18th. Canaccord Genuity Group reduced their price target on Biogen from $298.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. William Blair reiterated an “outperform” rating on shares of Biogen in a report on Monday, January 13th. Citigroup cut their target price on Biogen from $160.00 to $145.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Finally, Truist Financial lowered their price target on Biogen from $220.00 to $210.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Eighteen investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $213.15.

Biogen Stock Performance

Biogen stock opened at $115.17 on Friday. Biogen has a 1 year low of $110.04 and a 1 year high of $238.00. The company’s 50-day moving average is $136.74 and its two-hundred day moving average is $154.02. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. The company has a market cap of $16.86 billion, a PE ratio of 10.29, a PEG ratio of 1.51 and a beta of 0.06.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%.

Insider Activity

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the transaction, the director now directly owns 11,318 shares in the company, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Larson Financial Group LLC grew its holdings in Biogen by 640.9% during the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 141 shares during the period. Lee Danner & Bass Inc. acquired a new stake in shares of Biogen in the fourth quarter valued at approximately $25,000. Colonial Trust Co SC lifted its position in shares of Biogen by 9,300.0% in the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 186 shares during the last quarter. OFI Invest Asset Management acquired a new position in shares of Biogen during the 4th quarter worth approximately $32,000. Finally, SRS Capital Advisors Inc. bought a new stake in Biogen in the 4th quarter valued at $33,000. Institutional investors own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.